Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.37 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14949311 | 0.92 | CDK8 (0.40) | KDRCDK8FLT1SCN9ATTBK1 | |
| SCHEMBL14949190 | 0.90 | KDR (0.38) | KDRCDK8FLT1TTBK1TTBK2 | |
| SCHEMBL14949198 | 0.88 | KDR (0.39) | KDRFLT1TTBK1TTBK2PIK3CA | |
| SCHEMBL14949185 | 0.88 | KDR (0.37) | KDRCDK8FLT1TTBK1TTBK2 | |
| SCHEMBL14949184 | 0.87 | KMT2A (0.42) | KDRFLT1RAF1 | |
| SCHEMBL12336722 | 0.85 | BRAF (0.47) | KDRCDK8TTBK1RAF1BRAF | |
| SCHEMBL14949257 | 0.85 | KDR (0.42) | KDRCDK8FLT1TTBK1TTBK2 | |
| SCHEMBL14949256 | 0.84 | ROCK1 (0.39) | KDRCDK8FLT1EGFRPIK3CA | |
| SCHEMBL16786016 | 0.82 | PDGFRB (0.39) | KDRCDK8TTBK1TTBK2ALDH1A1 | |
| SCHEMBL14949242 | 0.82 | EGFR (0.41) | KDRCDK8TTBK1TTBK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | KDR 533/4885CDK8 49/4885FLT1 977/4885 |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | KDR 533/4885CDK8 49/4885FLT1 977/4885 |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | KDR 533/4885CDK8 49/4885FLT1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.